MA30890B1 - Compose indole - Google Patents

Compose indole

Info

Publication number
MA30890B1
MA30890B1 MA31871A MA31871A MA30890B1 MA 30890 B1 MA30890 B1 MA 30890B1 MA 31871 A MA31871 A MA 31871A MA 31871 A MA31871 A MA 31871A MA 30890 B1 MA30890 B1 MA 30890B1
Authority
MA
Morocco
Prior art keywords
indole compound
agent
prodruce
gluckkinase
prophylaxis
Prior art date
Application number
MA31871A
Other languages
English (en)
French (fr)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30890(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30890B1 publication Critical patent/MA30890B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA31871A 2006-10-19 2009-05-13 Compose indole MA30890B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19

Publications (1)

Publication Number Publication Date
MA30890B1 true MA30890B1 (fr) 2009-11-02

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31871A MA30890B1 (fr) 2006-10-19 2009-05-13 Compose indole

Country Status (26)

Country Link
US (4) US7652133B2 (enExample)
EP (2) EP2074119A1 (enExample)
JP (1) JP5260507B2 (enExample)
KR (1) KR101444486B1 (enExample)
CN (1) CN101573357B (enExample)
AU (1) AU2007310064B2 (enExample)
BR (1) BRPI0717722A2 (enExample)
CA (1) CA2666973C (enExample)
CL (1) CL2008001017A1 (enExample)
CR (1) CR10748A (enExample)
EC (1) ECSP099330A (enExample)
GE (1) GEP20115241B (enExample)
IL (1) IL198154A (enExample)
MA (1) MA30890B1 (enExample)
ME (1) MEP11809A (enExample)
MX (1) MX2009003972A (enExample)
MY (1) MY158052A (enExample)
NO (1) NO20091948L (enExample)
NZ (1) NZ576570A (enExample)
PE (1) PE20090884A1 (enExample)
RU (1) RU2454415C9 (enExample)
TN (1) TN2009000129A1 (enExample)
TW (1) TWI460176B (enExample)
UA (1) UA97257C2 (enExample)
WO (1) WO2008050821A1 (enExample)
ZA (1) ZA200902585B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011211A (es) * 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2178870B1 (en) * 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US20100267708A1 (en) * 2007-12-20 2010-10-21 Lg Life Sciences Ltd. Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
KR101098583B1 (ko) * 2008-01-04 2011-12-26 주식회사 엘지생명과학 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2009234666B2 (en) 2008-04-10 2014-02-20 Takeda Pharmaceutical Company Limited Fused ring compounds and use thereof
US8349886B2 (en) * 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5597200B2 (ja) * 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
EP2448921A4 (en) * 2009-04-09 2013-01-23 Msd Kk ARYLINDOLDERIVATE
JP5657578B2 (ja) 2009-06-09 2015-01-21 武田薬品工業株式会社 新規な縮合環化合物およびその用途
EA201270204A1 (ru) 2009-07-28 2012-08-30 Такеда Фармасьютикал Компани Лимитед Таблетка
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112012027648A2 (pt) 2010-04-27 2019-09-24 Takeda Pharmaceuticals Co composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto
CA2802483C (en) 2010-06-16 2017-10-24 Takeda Pharmaceutical Company Limited Crystal of amide compound
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012036293A1 (ja) 2010-09-17 2012-03-22 武田薬品工業株式会社 糖尿病治療剤
PE20140161A1 (es) 2010-11-30 2014-02-19 Takeda Pharmaceutical Compuesto biciclico
EA201391180A1 (ru) 2011-02-17 2014-01-30 Такеда Фармасьютикал Компани Лимитед Способ получения оптически активных производных дигидробензофурана
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6050238B2 (ja) * 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
WO2013061962A1 (ja) 2011-10-24 2013-05-02 武田薬品工業株式会社 二環性化合物
US9365540B2 (en) 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC RING CONNECTION
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CA2864990C (en) 2012-02-24 2021-03-02 Nobuyuki Takakura Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat)
CA2868713A1 (en) 2012-03-29 2013-10-03 Takeda Pharmaceutical Company Limited Aromatic ring compound
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
JPWO2013168760A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
US9440987B2 (en) 2012-05-10 2016-09-13 Takeda Pharmaceutical Company Limited Aromatic ring compound
KR102145641B1 (ko) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 고형 제제
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
ES2629729T3 (es) 2013-03-14 2017-08-14 Takeda Pharmaceutical Company Limited Derivados de espiro azetidina asoxazol y uso de los mismos como antagonistas de sstr5
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
UY35650A (es) 2013-07-09 2015-02-27 Takeda Pharmaceutical Compuesto heterocíclico
WO2015020184A1 (ja) 2013-08-09 2015-02-12 武田薬品工業株式会社 芳香環化合物
ES2835851T3 (es) 2013-08-22 2021-06-23 Lg Chemical Ltd Compuesto de indol amida como inhibidor de necrosis
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
UA129084C2 (uk) 2018-03-23 2025-01-08 Кармот Терап'Ютікс, Інк. Модулятори спряжених з g-білком рецепторів
WO2020045326A1 (ja) 2018-08-27 2020-03-05 株式会社スコヒアファーマ 安息香酸エステル化合物
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
JP7711074B2 (ja) 2020-02-07 2025-07-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
PH12022552562A1 (en) 2020-03-25 2022-12-19 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
WO2021193983A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qw dosing of gip receptor agonist peptide compounds and uses thereof
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
KR20240007251A (ko) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
CN120712261A (zh) 2022-12-22 2025-09-26 加舒布鲁姆生物公司 杂环的glp-1激动剂
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
AU2024311208A1 (en) 2023-06-30 2026-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
US20250188081A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
CN1221533C (zh) 1993-09-10 2005-10-05 卫材株式会社 7－氨基－1h－吲哚衍生物
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
TR200002447T2 (tr) * 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
AU2001252596A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
EP1935890B1 (en) 2005-09-30 2016-03-16 Msd K.K. 2-heteroaryl-substituted indole derivative
UY31293A1 (es) 2007-08-14 2009-03-31 Pirimidinas biciclicas fusionadas
AU2008288390A1 (en) 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2009050186A1 (en) 2007-10-18 2009-04-23 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles

Also Published As

Publication number Publication date
PE20090884A1 (es) 2009-08-05
UA97257C2 (en) 2012-01-25
CN101573357A (zh) 2009-11-04
ME00681B (me) 2011-12-20
US20090286975A1 (en) 2009-11-19
ECSP099330A (es) 2009-06-30
WO2008050821A1 (en) 2008-05-02
RU2454415C2 (ru) 2012-06-27
AU2007310064A1 (en) 2008-05-02
EP2508524A3 (en) 2012-10-24
CL2008001017A1 (es) 2009-04-24
EP2074119A1 (en) 2009-07-01
BRPI0717722A2 (pt) 2013-10-29
KR20090068292A (ko) 2009-06-25
US7652133B2 (en) 2010-01-26
JP5260507B2 (ja) 2013-08-14
US8410087B2 (en) 2013-04-02
US7777047B2 (en) 2010-08-17
IL198154A (en) 2014-08-31
TWI460176B (zh) 2014-11-11
US7718798B2 (en) 2010-05-18
CN101573357B (zh) 2013-01-23
CA2666973C (en) 2015-03-31
KR101444486B1 (ko) 2014-09-24
EP2508524A2 (en) 2012-10-10
MY158052A (en) 2016-08-30
US20080096877A1 (en) 2008-04-24
RU2009118602A (ru) 2010-11-27
MEP11809A (en) 2011-12-20
TW200825071A (en) 2008-06-16
CR10748A (es) 2009-05-20
GEP20115241B (en) 2011-06-10
CA2666973A1 (en) 2008-05-02
ZA200902585B (en) 2010-09-29
NZ576570A (en) 2010-11-26
US20100137610A1 (en) 2010-06-03
IL198154A0 (en) 2009-12-24
NO20091948L (no) 2009-07-13
AU2007310064B2 (en) 2013-03-28
AU2007310064A2 (en) 2009-06-04
TN2009000129A1 (en) 2010-10-18
MX2009003972A (es) 2009-04-27
JP2010506825A (ja) 2010-03-04
RU2454415C9 (ru) 2013-02-27
US20100144702A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
MA30890B1 (fr) Compose indole
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA29323B1 (fr) Composes de l'acide pyridylacetique
MA31169B1 (fr) Preparation solide comprenant de l'alogliptine et de la pioglitazone
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
MA32171B1 (fr) Compose heterocyclique
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA30456B1 (fr) Nouveau dérivé de coumarine présentant une activité anti-tumorale.
MA32965B1 (fr) Derives de sulfonamides
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA31419B1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
MA32164B1 (fr) Derive heterocyclique fusionne et son utilisation
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
TNSN07022A1 (fr) Derives de pyridine
MA30999B1 (fr) Composés.
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
MA34713B1 (fr) Compose bicyclique
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA65131B1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine